Bio-Rad Laboratories Inc. is a leading provider of life science research and clinical diagnostic products, founded in 1952 and headquartered in Hercules, California, United States. The company generates revenue through advanced laboratory instruments, reagents, and software sold to research institutions, hospitals, and biopharma companies. Under the leadership of CEO Norman H. Schwartz, Bio-Rad continues to drive innovation with flagship products including the GelDoc and Bio-Plex systems. With strategic investments in digital automation and next-generation diagnostics, the firm is well-positioned for sustained global growth.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
2,583,200
2,566,500
2,671,200
2,802,200
Cost of Sales
1,243,300
1,187,600
1,244,300
1,234,900
Gross Profit
1,339,900
1,378,900
1,426,900
1,567,300
Selling, General & Administrative Expenses
844,300
814,000
841,700
827,800
Research & Development Expenses
275,600
295,900
247,400
256,900
Other Operating Expenses
172,800
—
—
—
Operating Profit
47,200
269,000
337,800
482,600
Interest Expense
(49,000)
(48,900)
(49,400)
(38,100)
Non-Operating Income
997,300
(2,562,600)
(1,138,500)
(5,148,700)
Total Non-Operating Income
948,300
(2,611,500)
(1,187,900)
(5,186,800)
Income Before Provision for Income Taxes
995,500
(2,342,500)
(850,100)
(4,704,200)
Provision for Income Taxes
235,600
(498,300)
(212,800)
(1,076,700)
Consolidated Net Income
759,900
(1,844,200)
(637,300)
(3,627,500)
Net Income Attributable to Common Shareholders
759,900
(1,844,200)
(637,300)
(3,627,500)
Basic EPS
27.87
-65.36
-21.82
-121.79
Diluted EPS
27.85
-65.36
-21.82
-121.79
Basic Weighted Average Shares Outstanding
27,263
28,214
29,209
29,785
Diluted Weighted Average Shares Outstanding
27,281
28,214
29,209
29,785
Shares Outstanding
26,990
28,011
28,518
29,596
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
529,800
488,100
403,800
434,215
Short-Term Investments
1,010,900
1,176,400
1,208,900
1,362,020
Total Cash and Cash Equivalents
1,540,700
1,664,500
1,612,700
1,796,230
Accounts Receivable
460,600
452,500
489,000
494,645
Total Trade Receivables
460,600
452,500
489,000
494,645
Inventories
740,700
760,000
780,500
719,316
Other Current Assets
164,200
153,300
166,100
147,783
Total Current Assets
2,906,200
3,030,300
3,048,300
3,157,980
Net Property, Plant & Equipment
709,900
688,600
723,700
679,564
Net Intangible Assets
174,300
293,600
320,500
332,147
Goodwill
579,800
410,500
413,600
406,488
Long-Term Investments
6,103,600
4,839,200
7,698,100
8,830,890
Other Long-Term Assets
102,700
101,900
94,900
94,599
Total Assets
10,576,500
9,364,100
12,299,100
13,501,700
Accounts Payable
129,000
122,300
144,600
135,041
Accrued Expenses
172,300
124,200
139,900
194,790
Current Portion of Long-Term Debt
1,300
1,200
500
465
Current Portion of Leases
36,100
41,700
40,400
36,336
Other Current Liabilities
178,300
178,400
197,400
202,076
Total Current Liabilities
517,000
467,800
522,800
568,708
Long-Term Debt
1,201,700
1,200,400
1,199,100
1,197,720
Leases
145,700
131,400
165,500
153,597
Other Long-Term Liabilities
1,258,500
995,200
1,670,500
1,966,390
Total Long-Term Liabilities
2,605,900
2,327,000
3,035,100
3,317,710
Total Liabilities
3,122,900
2,794,800
3,557,900
3,886,410
Common Stock
—
—
—
3
Treasury Stock
(1,009,600)
(772,100)
(632,500)
(263,586)
Additional Paid-in Capital
476,000
463,200
449,100
447,454
Accumulated Other Comprehensive Income
(189,100)
(538,200)
(336,000)
(466,822)
Retained Earnings
8,176,300
7,416,400
9,260,600
9,898,200
Total Common Shareholders' Equity
7,453,600
6,569,300
8,741,200
9,615,250
Total Shareholders' Equity
7,453,600
6,569,300
8,741,200
9,615,250
Total Liabilities and Shareholders' Equity
10,576,500
9,364,100
12,299,100
13,501,700
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
759,900
(1,844,200)
(637,300)
—
Depreciation & Amortization
165,400
151,600
145,900
—
Share-Based Compensation Expense
58,000
62,300
61,300
—
Other Adjustments
(508,800)
2,122,300
956,200
—
Changes in Trade Receivables
19,600
16,200
11,400
—
Changes in Inventories
68,900
8,500
(46,300)
—
Changes in Accounts Payable
(100)
(40,900)
(51,800)
—
Changes in Income Taxes Payable
1,500
24,100
(21,300)
—
Changes in Other Operating Activities
(32,200)
(44,700)
(43,200)
—
Cash from Operating Activities
532,200
455,200
374,900
194,400
Capital Expenditure
(157,600)
(165,600)
(156,700)
(112,800)
Proceeds from Sale of Property, Plant & Equipment
100
100
200
200
Purchases of Intangible Assets
—
—
—
(1,500)
Purchases of Investments
(669,300)
(1,276,600)
(689,000)
(2,060,200)
Proceeds from Sale of Investments
855,600
1,305,300
863,200
1,066,000
Payments for Business Acquisitions
(218,500)
(23,400)
—
(100,700)
Proceeds from Business Divestments
—
—
2,500
1,400
Cash from Investing Activities
(189,700)
(160,200)
20,200
(1,207,600)
Issuance of Long-Term Debt
—
—
—
1,186,200
Repayments of Long-Term Debt
(500)
(400)
(500)
(500)
Net Issuance / (Repayments) of Long-Term Debt
(500)
(400)
(500)
1,185,700
Issuance of Common Shares
15,800
19,200
18,500
17,600
Repurchases of Common Shares
(295,500)
(203,600)
(428,700)
(215,700)
Net Issuance / (Repurchases) of Common Shares
(279,700)
(184,400)
(410,200)
(198,100)
Other Financing Activities
(3,000)
(34,000)
(14,900)
(14,000)
Cash from Financing Activities
(283,200)
(218,800)
(425,600)
973,600
Effect of Exchange Rate Changes on Cash and Cash Equivalents
(16,900)
9,200
400
3,000
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash